Drugs / Amino acid supplement
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06954662 | May → Sep 2025 overdue | Parkinson disease | UConn Health | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05599282 | Oct 2022 → Jan 2024 | Somatomedin, embryonic | ZandA Technologies, llc | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT01540773 Comparator | Oct → Dec 2011 | — | Pennington Biomedical Research Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Amino Acid Supplement | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05599282 ↗ |
| Modality | Other / unclassified | “novel blend of amino acids optimized to increase hGH release.” PMID 30893070 ↗ Jul 2020 |
| Route | Oral | “An orally administered supplement of the proprietary amino acid derivative” NCT01540773 ↗ |